Get started
Work

Crizotinib as Salvage and Maintenance With Allogeneic Stem Cell Transplantation for Refractory Anaplastic Large Cell Lymphoma

Year: 2014
Type: article
Study design: Case Report
Abstract: The NPM-ALK fusion protein is found in ALK(+) anaplastic large cell lymphomas harboring the t(2;5) chromosomal translocation. Patients harboring ALK translocations typically have an excellent prognosis with conventional chemotherapy and a reported 5-year survival rate of 70%. Although most patients with ALK(+) anaplastic large cell lymphoma have a good prognosis, some patients do not respond to standard therapies. In patients with refractory anaplastic large cell lymphoma who can achieve remission, allogeneic stem cell transplant is a potentially curative option. This article describes a patient with refractory ALK(+) anaplastic large cell lymphoma who experienced a complete response to the ALK inhibitor crizotinib and then underwent an allogeneic stem cell transplant followed by crizotinib maintenance therapy.
DOI: 10.6004/jnccn.2014.0034
Authors: James M. Cleary, Scott Rodig, Paul M. Barr, Atul B. Shinagare, Jeffrey W. Clark, Geoffrey I. Shapiro, Philippe Armand
Institutions: Brigham and Women's Hospital, Harvard University, University of Rochester Medicine, Massachusetts General Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, University of Rochester
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W1890593286
FWCI: 2.724
Cites: 15
Cited by: 24
Related to: 10